Extended Data Fig. 4. Doublet-base substitution signatures operative in clear cell renal cell carcinomas.

(a) Tumour mutation burden (TMB) plot showing the frequency and mutations per Mb for each of the decomposed DBS signatures. (b) Average relative attribution for doublet-base substitution (DBS) signatures across countries. Signatures contributing less than 5% on average are grouped in the ‘Other’ category, apart from signature DBS20. Category named ‘<95% confidence’ accounts for the proportion of mutation burden which could not be assigned to any signature with confidence level of at least 95%. (c) Decomposed DBS signatures, including reference COSMIC signatures as well as de novo signatures not decomposed into COSMIC reference signatures.